L
Luis M. Montuenga
Researcher at University of Navarra
Publications - 245
Citations - 10844
Luis M. Montuenga is an academic researcher from University of Navarra. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 48, co-authored 221 publications receiving 9205 citations. Previous affiliations of Luis M. Montuenga include Chartered Institute of Management Accountants & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Androgen-independent expression of adrenomedullin and peptidylglycine alpha-amidating monooxygenase in human prostatic carcinoma.
Nuria Jiménez,Ibane Abasolo,Johan Jongsma,Alfonso Calvo,Mercedes Garayoa,Theodorus H. van der Kwast,Gert J. van Steenbrugge,Luis M. Montuenga +7 more
TL;DR: It is demonstrated that preproAM and PAM expression in the human prostate is androgen‐independent and for the first time the expression of a novel PAM transcript in PC is reported, which has not been previously described in other tissues.
Journal ArticleDOI
TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.
Maria J. Pajares,Jackeline Agorreta,E Salvo,Carmen Behrens,I. I. Wistuba,Luis M. Montuenga,Ruben Pio,Ruben Pio,A Rouzaut,A Rouzaut +9 more
TL;DR: TGFBI may be useful for the identification of a subset of NSCLC who may benefit from adjuvant therapy and multivariate analysis demonstrated that high TGFBI expression is an independent predictor of better survival in patients.
Journal ArticleDOI
Expression of αCP‐4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells
TL;DR: In this article, the authors evaluated the effect of alpha CP-4 on the tumorigenic capacity of lung cancer cells and found that alphaCP-4 expression caused cell cycle arrest in G(2)/M in 3 out of the 7 lung cancer cell lines studied, while no effect on apoptosis was observed.
Journal ArticleDOI
Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma
Rafael Ikemori,Marta Gabasa,Paula Duch,Miguel Vizoso,Paloma Bragado,Marselina Arshakyan,Iuliana-Cristiana Luis,Albert Marín,Sebastian Moran,Manuel Castro,Gemma Fuster,Sabrina Gea-Sorli,Toni Jauset,Laura Soucek,Laura Soucek,Luis M. Montuenga,Luis M. Montuenga,Manel Esteller,Eduard Monsó,Victor I. Peinado,Victor I. Peinado,Pere Gascón,Cristina Fillat,Frank Hilberg,Noemí Reguart,Jordi Alcaraz,Jordi Alcaraz +26 more
TL;DR: The results unveil that the histotype-specific regulation of tumor fibrosis in lung cancer is mediated through differential SMAD3 promoter methylation in TAFs, and provide new mechanistic insights on the selective poor response of SCC-TAFs to nintedanib.
Journal ArticleDOI
Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates.
Isabel Zudaire,Lozano,Madeline Vazquez,Maria J. Pajares,Jackeline Agorreta,Ruben Pio,Javier J. Zulueta,David F. Yankelevitz,C. I. Henschke,Luis M. Montuenga +9 more
TL;DR: Molecular analysis of FNA specimens may provide useful information at preoperative stages and a good prognostic profile in subsolid early detected adenocarcinomas is suggested.